Casanova, María JoséChaparro, MaríaMínguez, MiguelRicart, ElenaTaxonera, CarlosGarcía-López, SantiagoGuardiola, JordiLópez-San Román, AntonioIglesias, EvaBeltrán, BelénSicilia, BeatrizVera, María IsabelHinojosa, JoaquínRiestra, SabinoDomènech, EugeniCalvet, XavierPérez-Calle, José LázaroMartín-Arranz, María DoloresAldeguer, XavierRivero, MontserratMonfort, DavidBarrio, JesúsEsteve, MaríaMárquez, LucíaLorente, RufoGarcía-Planella, Estherde Castro, LuisaBermejo, FernandoMerino, OlgaRodríguez-Pérez, AntonioMartínez-Montiel, PilarVan Domselaar, ManuelAlcaín, GuillermoDomínguez-Cajal, ManuelMuñoz, CarmenGomollón, FernandoFernández-Salazar, LuisGarcía-Sepulcre, Mariana FeRodríguez-Lago, IagoGutiérrez, AnaArgüelles-Arias, FedericoRodriguez, CristinaRodríguez, Gloria EstherBujanda, LuisLlaó, JordinaVarela, PilarRamos, LauraHuguet, José MaríaAlmela, PedroRomero, PatriciaNavarro-Llavat, MercèAbad, ÁguedaRamírez-de la Piscina, PatriciaLucendo, Alfredo JSesé, EvaMadrigal, Rosa EvaCharro, MaraGarcía-Herola, AntonioPajares, RamónKhorrami, SamGisbert, Javier P2023-01-252023-01-252020http://hdl.handle.net/10668/14490The effectiveness of the switch to another anti-tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance to or failure of a previous anti-TNF agent in inflammatory bowel disease (IBD) patients. We included patients diagnosed with IBD from the ENEIDA registry who received another anti-TNF after intolerance to or failure of a prior anti-TNF agent. A total of 1122 patients were included. In the short term, remission was achieved in 55% of the patients with the second anti-TNF. The incidence of loss of response was 19% per patient-year with the second anti-TNF. Combination therapy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.8-3; P Approximately half of the patients who received a second anti-TNF achieved remission; nevertheless, a significant proportion of them subsequently lost response. Combination therapy and type of IBD were associated with loss of response. Remission was achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant proportion of them subsequently lost response.enCC0 1.0 Universalhttp://creativecommons.org/publicdomain/zero/1.0/Crohn’s diseaseanti-TNFinflammatory bowel diseaseswitchulcerative colitisAdalimumabAdolescentAdultAgedChildChild, PreschoolColitis, UlcerativeCrohn DiseaseFemaleHumansInfliximabKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMultivariate AnalysisProspective StudiesRegistriesRemission InductionSpainTumor Necrosis Factor InhibitorsYoung Adultresearch article31504569open access10.1093/ibd/izz1921536-4844http://diposit.ub.edu/dspace/bitstream/2445/173702/1/692115.pdf